Do Not Open the Door
By Marcy Darnovsky,
Southwestern Medical Perspectives
| 12. 04. 2019
Should CRISPR be used to alter the genes and traits of future children and generations? Dozens of nations have considered this prospect and decided that manipulating the human germline should be legally off limits. The U.S. and China have not.
Some gene-editing enthusiasts now want to reopen the question. The answer will affect us all and shape the future. Yet despite the stakes being so high, many discussions of heritable genome editing are distorted by dubious assumptions. The claim that editing human embryos is needed to save babies from inherited disease and could “reduce human suffering in profound and meaningful ways,” for example, is misleading for several reasons.
First is the substantial risk of introducing rather than preventing harm. Editing an embryo’s genes can go wrong in multiple ways, including off-target edits, on-target but inaccurate edits, and a condition called mosaicism that produces a mix of altered and unaltered cells in an embryo – and in the resulting child. No one knows what the health effects of these unintended changes might be, for that child or for future generations.
Second: Safe options...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...